Dr Reddy’s Laboratories has launched oral semaglutide tablets in India, giving patients a new and more convenient option for managing type 2 diabetes. The medicine belongs to the GLP-1 class of drugs, which are widely used to control blood sugar levels and also help with weight management.
The company is offering the drug under the brand name Obeda. Unlike most GLP-1 treatments that require injections, this version comes in tablet form, which is expected to be easier for many patients who are uncomfortable with needles or long-term injections.
Dr Reddy’s has priced each tablet at around ₹99, positioning it as a more affordable alternative to imported or branded versions currently available in the market. The company said the goal is to improve access to modern diabetes care for a larger section of patients in India, where diabetes cases continue to rise sharply.
Semaglutide works by mimicking a natural hormone in the body that helps regulate insulin, control appetite, and slow digestion. This helps lower blood sugar levels and can also support weight loss in many patients, making it one of the most in-demand treatments globally for type 2 diabetes.
Doctors say GLP-1 medicines have become increasingly important in recent years because they not only manage diabetes but also address related conditions like obesity, which often goes hand in hand with it. However, the high cost of such drugs has limited their reach in many countries, including India.
The introduction of an oral version is expected to improve acceptance among patients, especially those who prefer tablets over injections. Health experts believe this could encourage more people to stick to long-term treatment plans.
The company plans to make the tablets available through pharmacies across India, but only with a doctor’s prescription. Medical professionals have also cautioned that the drug should be taken under proper supervision, as dosage and suitability depend on individual health conditions.
Also Read: Apple blocks $2.2 bn app store fraud in 2025